


1 **Supplementary material**

2 **Supplementary 1: Data cleaning**

3 **Manual data cleaning** was carried out according to the following rules:

4 VA: Missing or zero VA entries were manually checked in paper notes. If available from
5 within 7 days before injection date, the respective VA was manually entered. Eyes with VA <
6 25 letters (below National Institute for Health and Care Excellence criteria for treatment of
7 neovascular AMD) at first presentation were checked manually. VA measured in Snellen
8 were converted to ETDRS letters according to Gregori et. al.[35] Visual acuities below
9 measurable ETDRS letters were converted to logMAR 2.0/-15 letters, logMAR 2.3/-30 letters
10 and logMAR 2.7/-50 letters for count fingers, hand movements, and light perception
11 respectively. Patient age: All patients <55 or >100 years of age at first presentation were
12 checked manually to address misdiagnosis. Injection number: All eyes having received ≥ 50
13 injections were manually checked to avoid errors of manual input of legacy injection
14 numbers.




15

16 sFigure 1: Consort flow diagram data of data collection and cleaning

17 **Supplementary 2: Treatment guidelines for aflibercept**

18



19
20
21
22
23
24
25

sFigure 2: Treatment flow chart for aflibercept treatment in new cases of neovascular AMD at Moorfields Eye Hospital. Derived from *Guidelines for the intravitreal service for the treatment of age-related macular degeneration (version 2.0)*. AMD - Age related macular degeneration